Novartis to acquire neuroscience company Cadent Therapeutics in $770m worth deal
Novartis acquisition of Cadent Therapeutics : Swiss pharma giant Novartis has agreed to acquire a US neuroscience company Cadent Therapeutics, in a deal worth up to $770 million. The consideration includes an upfront payment of $210 million and up to $560 million in milestone payments. Cadent Therapeutics was launched about three years ago via the […]
Novartis acquisition of Vedere Bio : US-based stealth-stage company Vedere Bio has been acquired by Swiss pharma giant Novartis in a deal worth up to $280 million, for its preclinical intravitreally-injected AAV gene therapy programs. The company is engaged in advancing photoreceptor-protein-based optogenetic therapies that are intravitreally delivered to the retina for restoring functional vision. […]
Continue reading …Novartis reports positive results for Aimovig in phase 2 episodic migraine trial
October 4, 2020 No Comment
Novartis said that a five-year phase 2 clinical trial of migraine prevention drug Aimovig (erenumab-aooe) has delivered strong long-term safety and efficacy results in patients with episodic migraine (EM). The results of the mid-stage trial – NCT01952574 are being presented by the Swiss drugmaker at the 18th Migraine Trust Virtual Symposium. The five-year, open-label treatment […]
Continue reading …BioNTech to acquire Novartis’ Marburg manufacturing plant to expand production of COVID-19 vaccine candidates
September 18, 2020 No Comment
Biopharmaceutical New Technologies (BioNTech) has agreed to acquire a GMP certified manufacturing facility in Marburg, Germany from Novartis to expand the production capacity of its BNT162 COVID-19 vaccine candidates. The financial terms of the deal were not revealed by the parties. BioNTech said that the production capacity of its five mRNA COVID-19 vaccine candidates under […]
Continue reading …
Kesimpta FDA approval for RMS: Novartis has bagged approval from the US Food and Drug Administration (FDA) for its blood cancer drug Kesimpta (ofatumumab, formerly OMB157) for the treatment of relapsing forms of multiple sclerosis (RMS). The approval is for the use of the anti-CD20 monoclonal antibody (mAb) as a subcutaneous injection in clinically isolated syndrome, […]
Continue reading …
TScan Therapeutics has partnered with Swiss pharma giant Novartis to discover and develop novel TCR-engineered T cell receptor therapies for the treatment of solid tumors using the former’s TScan Discovery Platform. The TScan platform will be used for discovering novel cancer antigens that can be targeted by TCR-based therapies. TScan Therapeutics will be engaged in […]
Continue reading …
Ruxolitinib coronavirus clinical trial : Incyte revealed that it is working with the US Food and Drug Administration (FDA) to launch the phase 3 RUXCOVID clinical trial to assess the efficacy and safety of ruxolitinib (Jakafi) plus standard-of-care (SoC) in patients with COVID-19 associated cytokine storm syndrome. The ruxolitinib plus standard-of-care will be compared to […]
Continue reading …Novartis to acquire The Medicines Company for $9.7bn with eye on inclisiran
November 25, 2019 No Comment
Novartis acquisition of The Medicines Company : Swiss drugmaker Novartis signed a deal worth $9.7 billion to acquire US biopharma company The Medicines Company, as per the latest pharma acquisition news. As per the terms of the all-cash deal, Novartis will acquire The Medicines Company for $85.00 per share. The Medicines Company, which is headquartered […]
Continue reading …Novartis bags Adakveo FDA approval to reduce VOCs in sickle cell disease
November 16, 2019 No Comment
Adakveo FDA approval : Swiss drugmaker Novartis has bagged approval for Adakveo (crizanlizumab-tmca) from the US Food and Drug Administration (FDA) for its use in sickle cell disease. Formerly known as SEG101, Adakveo has been indicated to be used for bringing down the frequency of vaso-occlusive crises (VOCs), or pain crises, in patients, aged 16 […]
Continue reading …
Sandoz, the generic drug business of Novartis has agreed to acquire the Japanese business of Aspen Global Incorporated (AGI), a fully owned subsidiary of Aspen Pharmacare in a deal valued up to €400 million, as per the latest pharma acquisition news. The acquisition includes shares in Aspen Japan and associated assets held by the South […]
Continue reading …
Business News Today
- Dr. Reddy’s Laboratories gets DCGI nod for phase 3 trial of Sputnik V vaccine
- Bharti Airtel sells stake in Loan Singh creator Seynse Technologies
- Dabur India launches Dabur 100% Pure Cow Ghee
- Infosys to acquire assets of Australian design agency Carter Digital
- ICICI Bank Niyo Bharat Payroll Card launched for MSME workers
- Huntsman wraps up $250m acquisition of Gabriel Performance Products
- Janssen secures DARZALEX FASPRO FDA approval for AL amyloidosis
- Dr. Reddy’s reports success for Russian Covid-19 vaccine Sputnik V
- TCS rolls out Autoscape solution suite for autonomous and connected vehicle experiences
- Infosys Q3 2020 results : Indian IT services giant reports $705m net profit
